BOSTON--Researchers at New England Deaconess Hospital are seeking patients with Hodgkin's disease, non-Hodgkin's lymphoma, acute myelogenous leukemia (AML), and chronic myelogenous leukemia (CML) for an FDA-sponsored study of a humanized anti-Tac (interleukin-2 receptor) monoclonal antibody. The phase Ib/II multidose trial will study tolerance, therapeutic efficacy, and biological efficacy.
The protocol (92-0205-34) calls for patients over the age of 18 with a life expectancy greater than 2 months and confirmed Tac on malignant cells, except for Hodgkin's disease patients, for which all R-S (Reed-Sternberg) cells are Tac-positive. Also, patients must be able to have continuous local access for 1 month.
Hodgkin's disease patients (25 to be enrolled) must have failed first-line therapy and one salvage attempt. Non-Hodgkin's lymphoma patients with aggressive disease must have failed first-line therapy; if indolent, any patient is eligible. All CML patients (eight to be enrolled) are eligible. AML patients (eight to be enrolled) must have failed first-line therapy or be in first or later relapse.
For more information, contact Dan Hagg, New England Deaconess Hospital, 21-27 Burlington Avenue, 5th Floor, Boston, MA 02215. Phone: 617-632-0316.
